Introduction
============

Cataract is an opacification of the lens that leads to decreased visual acuity (VA) and functional disability.[@b1-opth-12-439] Cataract is a common and significant cause of visual impairment and the leading cause of preventable blindness worldwide.[@b2-opth-12-439] Astigmatism, resulting typically from anterior corneal asymmetry, leads to decreased image quality.[@b3-opth-12-439] Astigmatism is measured in both magnitude and direction. Astigmatism of 1--1.5 D or more negatively impacts reading performance and nighttime-driving ability.[@b4-opth-12-439],[@b5-opth-12-439] Astigmatism in patients with cataract further reduces VA and adversely impacts functional and contrast VA. Uncorrected astigmatism can lead to decreased vision and affect patients' vision-related quality of life (QoL) and well-being.[@b6-opth-12-439]

The prevalence of astigmatism and the associated economic and humanistic burden in patients undergoing cataract surgery have been recognized in the international literature, but data from these studies have not been systematically reviewed. Therefore, this systematic literature review was conducted to address this gap and report the published evidence on prevalence, economic burden, and humanistic burden of astigmatism in cataract patients.

Materials and methods
=====================

This review followed a standard, systematic review methodology endorsed by the Cochrane Collaboration[@b7-opth-12-439] and the National Institute for Health and Care Excellence, the health-technology assessment body of the UK.[@b8-opth-12-439] Findings from this review were reported in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines ([Figure 1](#f1-opth-12-439){ref-type="fig"}).[@b9-opth-12-439]

A comprehensive literature search was conducted using predefined search strings ([Table 1](#t1-opth-12-439){ref-type="table"}) in electronic databases (Medline, Medline In-Process, Embase, and the Cochrane Library). The key search terms focused on identifying studies on prevalence, direct and indirect treatment costs, and patient QoL in cataract patients with astigmatism. All studies reporting prevalence, economic burden, and humanistic burden in cataract patients with preexisting astigmatism (PEA) published in English from 1996 to September 2015 were included. Animal and in vitro studies, non-English-language studies, studies published prior to 1996, and studies that did not meet research objectives were excluded. In addition, abstracts and posters from the following conferences (held from 2010 until September 2015) were searched: American Association of Ophthalmology Congress, World Ophthalmology Congress, Royal College of Ophthalmologists UK Congress, and the European Association for Vision and Eye Research Congress. Reference lists of relevant studies, systematic reviews, or literature reviews were also screened to identify any publication not captured through the systematic search.

Following the search process, we screened abstracts of all publications, and excluded publications for further review if they did not fulfill the eligibility criteria. Full-text copies of all publications that fulfilled the eligibility criteria or those lacking sufficient information in the abstract for exclusion were obtained and reviewed, and the eligibility criteria were reapplied. Finally, data were extracted from eligible publications for full review. For the economic burden section, costs reported across studies were inflated to 2017 US\$ using consumer price indices published by the Organisation for Economic Co-operation and Development[@b10-opth-12-439] and currency-exchange rates.[@b11-opth-12-439],[@b12-opth-12-439]

Results
=======

The literature search yielded 3,649 citations, of which 31 from 32 publications were identified for inclusion in this review and data extraction performed ([Figure 1](#f1-opth-12-439){ref-type="fig"}). In total, 18 studies from 19 publications[@b13-opth-12-439]--[@b31-opth-12-439] (one study reported in two publications) reporting prevalence were identified. Five studies[@b32-opth-12-439]--[@b36-opth-12-439] reporting economic burden and eight studies[@b37-opth-12-439]--[@b44-opth-12-439] reporting humanistic burden were identified.

Prevalence of preexisting astigmatism in cataract
-------------------------------------------------

[Table 2](#t2-opth-12-439){ref-type="table"} provides a summary of studies reporting the prevalence of PEA in cataract patients. Of 18 studies included in this review, nine were retrospective, five cross-sectional, and four prospective in design. The reported mean age of the astigmatic cataract patients was 60.6--75.5 years. A higher proportion of females compared to males reported having PEA and cataract: 53.7%--68.2% across the studies. PEA was measured in cylinder diopters, with reported means of 0.79--1.09 D.

Across countries, the overall prevalence of astigmatism in cataractous eyes (of any cylinder magnitude) was as follows: Croatia 99%,[@b17-opth-12-439] UK 94%,[@b22-opth-12-439] South Korea 91.8%,[@b26-opth-12-439] and Spain 86.8%,[@b18-opth-12-439] indicating that astigmatism is a very common refractive error alongside cataract. However, not all patients would require correction for their astigmatism. In general, cataract and refractive surgeons would aim to correct PEA if it is above a clinically important threshold; however, there is no universally accepted clinically important cylinder diopter-threshold to identify treatment-eligible cataract patients with PEA.

Many studies reported prevalence as a proportion of cataract eyes ≥1 D of PEA.[@b13-opth-12-439],[@b16-opth-12-439]--[@b19-opth-12-439],[@b23-opth-12-439]--[@b28-opth-12-439],[@b31-opth-12-439] Using a ≥1 D threshold, the prevalence of PEA ranged between 23%[@b26-opth-12-439] in South Korea and 47%[@b31-opth-12-439] in China ([Figure 2](#f2-opth-12-439){ref-type="fig"}). At least two studies reported this prevalence as patients who could benefit from PEA correction during cataract surgery.

Lyall et al proposed a widely used disease-severity classification approach in clinical practice, ie, categorizing disease severity into mild, moderate, and severe categories for PEA in cataract patients' severity classification.[@b24-opth-12-439] The following thresholds to classify PEA in cataract patients into three categories were proposed: \<1.5 D (mild), ≥1.5--\<2.5 D (moderate), and ≥2.5 D (significant). We applied this classification to the data reported in various studies, and generated uniform prevalence figures across geographies. With this approach, the prevalence of mild PEA (\<1.5 D) ranged between 74.6%[@b31-opth-12-439] (China) and 89.6%[@b13-opth-12-439],[@b26-opth-12-439] (South Korea), moderate PEA (≥1.5--\<2.5 D) 8.1%[@b10-opth-12-439],[@b13-opth-12-439] (Sweden) and 18.6%[@b31-opth-12-439] (China), and significant PEA (≥2.5 D) 2%[@b26-opth-12-439] (South Korea) and 6.8%[@b28-opth-12-439] (Thailand) ([Figure 3](#f3-opth-12-439){ref-type="fig"}). It is evident from the reported data that across countries, the prevalence of clinically relevant PEA in cataract patients is substantial and that these patients could benefit from astigmatism correction during cataract surgery. None of the prevalence studies included in this review reported the prevalence of postoperative astigmatism, which could have provided some insights into astigmatism-correction patterns during cataract surgery.

Astigmatism differs from other common refractive conditions (hyperopia and myopia) in that the refractive error is measured in both magnitude and direction. In addition, it can also be measured based on corneal topographical symmetry: irregular astigmatism, which does not conform to any geometric appearance, and regular astigmatism, which is symmetrical across the meridian. Regular astigmatism is defined as with the rule (WTR) when the axis of the correcting minus cylinder was within 180°±30° (the steep meridian of the cornea being within 90°±30° in this case), against the rule (ATR) when the correcting minus-cylinder axis was within 90°±30°, and oblique astigmatism (OA) if it was neither WTR nor ATR.[@b16-opth-12-439] The prevalence of astigmatic cataract eyes by the type of astigmatism orientation (WTR, ATR, and OA) was reported in five studies and is presented in [Figure 4](#f4-opth-12-439){ref-type="fig"}.

The proportion of astigmatic cataract eyes with ATR stigmatism was 39% in Italy,[@b16-opth-12-439] 45% in Croatia,[@b17-opth-12-439] 50% in New Zealand,[@b29-opth-12-439] and 52.4% in Thailand[@b28-opth-12-439] and China.[@b31-opth-12-439] The proportion of astigmatic cataract eyes with WTR astigmatism was 15% in New Zealand,[@b29-opth-12-439] 22% in Croatia,[@b17-opth-12-439] 22.7% in Thailand,[@b28-opth-12-439] 30.4% in China,[@b31-opth-12-439] and 44% in Italy.[@b16-opth-12-439] While the proportion of astigmatic cataract eyes with OA was 15% in New Zealand,[@b29-opth-12-439] 17% in Italy,[@b16-opth-12-439] 17.2% in China,[@b31-opth-12-439] 24.9% in Thailand,[@b28-opth-12-439] and 32% in Croatia.[@b17-opth-12-439] Based on the reported data, ATR is the most common subtype of regular PEA in cataract patients. These prevalence data on astigmatism subtypes can be helpful for surgeons to plan optimized astigmatism correction during cataract surgery.

Correlations between age and the prevalence and/or severity of PEA in cataract patients were reported in eight studies (four each from Europe and Asia).[@b14-opth-12-439],[@b16-opth-12-439],[@b18-opth-12-439],[@b19-opth-12-439],[@b22-opth-12-439],[@b24-opth-12-439],[@b28-opth-12-439],[@b31-opth-12-439] A small increment in the magnitude of astigmatism with age was observed in a Spanish cohort.[@b18-opth-12-439] Khan and Muhtaseb[@b22-opth-12-439] reported a gradual increase in the prevalence and severity of PEA with age in the UK population, but Lyall et al,[@b24-opth-12-439] also a UK-based study, did not report such a trend. Similarly, De Bernardo et al did not identify an increase of astigmatism with age in an Italian cohort either.[@b16-opth-12-439] However, this trend appears to be consistently reported across Asia. In a Thai cohort, a significant correlation between astigmatism severity and age was observed (*P*\<0.001).[@b28-opth-12-439] Similar positive results were observed in all the three studies from China, which reported a significant increase in PEA severity and age.[@b14-opth-12-439],[@b19-opth-12-439],[@b31-opth-12-439] A trend was also observed between advancing age and increasing prevalence of ATR astigmatism in all the studies that reported data on both parameters.[@b16-opth-12-439],[@b18-opth-12-439],[@b19-opth-12-439],[@b21-opth-12-439],[@b24-opth-12-439] Some studies also reported correlations between orientation of regular astigmatism and age. An increase in the frequency of ATR astigmatism was observed with advancing age in cataract patients.[@b16-opth-12-439],[@b18-opth-12-439],[@b19-opth-12-439],[@b21-opth-12-439],[@b24-opth-12-439] Several studies also reported associations of age and the degree of astigmatism, with characteristic changes in the astigmatic axis from WTR to ATR with advancing age.[@b45-opth-12-439]--[@b48-opth-12-439] Based on the review of evidence, the correlation between advancing age and PEA severity remains inconclusive, as findings differed among studies conducted across similar and different geographies. However, cataract being a primarily an age-related condition, the evidence indicates that surgeons planning cataract surgery in older patients should consider PEA levels and plan for the optimum treatment strategy to improve postoperative visual outcomes.

Economic burden
---------------

The economic burden of cataract has been widely recognized[@b49-opth-12-439],[@b50-opth-12-439] and acknowledged by the ophthalmologic community;[@b51-opth-12-439]--[@b53-opth-12-439] however, the economic burden of preexisting and postoperative astigmatism is not widely known. In our search, we identified five studies that reported direct and indirect cost burdens of astigmatism in cataract patients.[@b32-opth-12-439]--[@b36-opth-12-439] [Table 3](#t3-opth-12-439){ref-type="table"} details the characteristics of the included studies. None of the studies reported preoperative economic burden of astigmatism in cataract patients. The studies published were health-economics analyses that reported the estimated cost of astigmatism correction during cataract surgery, evaluated the cost-effectiveness or cost consequence of astigmatism correcting treatment options, and estimated the cost burden of correcting postoperative residual or uncorrected astigmatism with spectacles.

Laurendeau et al conducted a cost--consequence analysis in four European countries (France, Germany, Italy, and Spain) from a societal perspective, comparing monofocal intraocular lenses (IOLs) to toric IOLs with a focus on their ability to reduce spectacle dependence.[@b32-opth-12-439] The rate of spectacle replacement was estimated to be 2--3 years for many patients (33%--48%). A simulated cohort of astigmatic, bilateral IOL recipients undergoing cataract surgery was followed up with a time horizon of 30 years in a Markov model. In this analysis, the estimated cost of cataract surgery per patient, including cost of IOLs (both toric and standard monofocal IOLs considered at parity price), ranged from \$1,510 in Spain to \$1,740 in Germany. Patients implanted with toric IOLs in France, Spain, Germany, and Italy were estimated to spend between \$1,786 and \$3,605 on spectacles, while in patients implanted with monofocal IOLs, the costs were estimated to be between \$2,313 and \$4,629. In all four countries, the lifetime cost-savings associated with toric IOLs ranged from \$443 to \$978. Savings in the toric IOL group observed were due to less expensive vision correction with spectacles compared to the standard monofocal IOL group.[@b32-opth-12-439]

Pineda et al conducted a cost-effectiveness analysis comparing toric IOLs with monofocal IOLs (with or without intraoperative refractive correction \[IRC\] using limbal relaxing incision/peripheral corneal relaxing incision \[PCRI\]).[@b33-opth-12-439] They built a decision-analysis model reflecting the treatment pathway for cataract patients with astigmatism from the US health-care perspective over a span of 18 years. Patients with toric IOLs were estimated to achieve an incremental gain of 13% with regard to spectacle independence versus those with monofocal IOLs without IRC and 4% compared to those with IRC. The toric IOL group was estimated to achieve an incremental gain of 9% in uncorrected VA (UCVA) ≥20/25 versus the monofocal IOL group without IRC and 5% compared to the group with IRC. Incremental quality-adjusted life-year (QALY) gains in patients with toric IOLs versus monofocal IOLs without and with IRC were reported to be 0.1 and 0.06 QALYs, respectively. Postsurgery total lifetime costs associated with toric IOLs were comparable with monofocal IOLs, but costs associated with IRC along with monofocal IOLs were higher than those with toric IOLs or monofocal IOLs alone. In addition, the lifetime cost of spectacle use after cataract surgery was estimated to be higher with monofocal IOLs compared to toric IOLs. Patients with toric IOLs saved \$34 over their lifetime compared with those using monofocal IOLs without IRC. The cost savings were sensitive to UCVA achieved (\$425 more if UCVA ≥20/25), cost of the toric IOLs, and the likelihood of achieving spectacle independence. Compared to the costs in patients with IRC and monofocal IOLs, patients with toric IOLs saved \$230 over their lifetime. The savings reflected higher spectacle independence in the toric IOL group. The lifetime cost saving per patient could be considered negligible, but it is important to note that the toric IOL group also achieved a higher QALY gain for the duration of this model, indicating that toric IOLs were a dominant treatment strategy for cataract patients with PEA.[@b33-opth-12-439]

Similarly, Ochoa et al conducted a cost-effectiveness study in Colombia to evaluate the cost-effectiveness of toric IOLs versus the use of conventional monofocal IOLs in patients with cataract and PEA \>0.75 D from the perspective of third-party payer.[@b34-opth-12-439] A decision-tree model simulated the cataract-surgery intervention over a time horizon of 5 years. The cumulative cost of treatment of patients with cataract and PEA \>0.75 D with toric IOLs was estimated to be \$1,172 compared to \$786 with traditional monofocal IOLs up to 5 years after cataract surgery. The incremental cost-effectiveness ratio with toric IOLs was \$573 per year of normal vision without additional support compared to traditional monofocal IOLs. A linear relationship between preoperative PEA diopters and ICER was observed, indicating that PEA correction in cataract patients with toric IOL was more cost-effective in patients at the higher end of the severity spectrum.[@b34-opth-12-439]

As a refractive error, astigmatism can affect patients' vision and lead to difficulty in performing job-related activities. However, it is important to note that cataract patients are usually older and mostly outside the workforce population, and thus direct productivity loss could be considered of little relevance to society. On the other hand, their caregivers could be part of the working-age population and the condition could be associated with indirect productivity loss. To estimate the direct and indirect costs and associated productivity loss for astigmatic cataract patients, Kim et al conducted a cross-sectional survey in South Korea in cataract patients with and without astigmatism (n=150).[@b35-opth-12-439] They reported that time spent on health-care appointments related to astigmatism correction with spectacles was 30--60 minutes for 41% of patients, while 15% of patients spent over 90 minutes. A relative accompanied two-thirds of patients for optometrist appointments. They also reported that patients with post-cataract surgery astigmatism paid approximately twice as much for their spectacles compared to patients without postoperative astigmatism (\$452 and \$223, respectively). The additional postsurgical lifetime cost of spectacles in cataract patients to correct astigmatism was \$2,164 per patient, which was greater than the out-of-pocket costs associated with toric IOLs.[@b35-opth-12-439]

Health-care resource utilization is an important contributor to the direct health-care costs and could affect hospital budgets. Resource utilization in astigmatic cataract patients was studied and reported by Colin et al.[@b36-opth-12-439] Findings suggested that astigmatic cataract patients had longer hospital stay, more comorbidities, and a significant increase in procedures compared to cataract patients without astigmatism. Further, the cost of procedures was higher for astigmatic cataract patients.[@b36-opth-12-439] However, these data need to be interpreted with caution, since cataract surgery is almost universally an outpatient procedure in the majority of countries. This review did not identify studies that reported health-care resource utilization in astigmatic cataract patients in the postoperative period, which could have provided some insights into the impact of uncorrected astigmatism on health-care resources.

Humanistic burden
-----------------

Cataract is known to have impact on patients' QoL.[@b54-opth-12-439] The QoL of cataract patients is further aggravated by the presence of astigmatism. Astigmatism-related vision distortion can lead to decreased visual performance, which increases spectacle dependence and can affect vision-related QoL. As with economic burden, the impact of astigmatism on patients' vision-related QoL has not been widely acknowledged. We identified eight studies that reported the humanistic burden of astigmatism in patients with cataract.[@b37-opth-12-439]--[@b44-opth-12-439]

[Table 4](#t4-opth-12-439){ref-type="table"} provides a summary of the included evidence. Five studies reported data on patient satisfaction with vision,[@b38-opth-12-439],[@b40-opth-12-439]--[@b43-opth-12-439] and six studies on spectacle dependence in astigmatic cataract patients.[@b37-opth-12-439]--[@b41-opth-12-439],[@b43-opth-12-439] Only one study reported the effect of astigmatism on the risk and rate of falls in patients with cataract.[@b44-opth-12-439] [Table 5](#t5-opth-12-439){ref-type="table"} summarizes the instruments used to assess vision-related QoL in studies included in this review. Different measures were used to evaluate patient satisfaction with vision: the Patient Satisfaction Scale (0--10),[@b38-opth-12-439],[@b40-opth-12-439],[@b43-opth-12-439] standardized 42-item National Eye Institute Refractive Error Quality of Life (NEI RQL-42) questionnaire,[@b41-opth-12-439],[@b42-opth-12-439] Visual Tasks Difficulty Assessment (VISTAS) questionnaire,[@b43-opth-12-439] and 14-item Visual Function (VF-14) index.[@b38-opth-12-439] The main findings from each study are reported separately in the following paragraphs, since heterogeneous study designs and different outcomes measures used to report spectacle dependence, satisfaction with vision, and QoL did not allow for evidence summary.

Spectacle independence is becoming an increasingly important outcome in cataract surgery, including in astigmatic cataract patients.[@b41-opth-12-439] Lane et al conducted a prospective multicenter double-arm study in patients with cataract and corneal astigmatism to assess spectacle independence and patient satisfaction with vision over 6 months of follow-up in patients with bilateral toric (n=40 patients) and spherical (n=22 patients) IOLs.[@b37-opth-12-439] At 1 month postsurgery, spectacle independence (defined as no use of spectacles for distance vision) was relatively higher in patients who received toric IOLs (97% of patients) compared to those who received spherical IOLs (50% of patients). At the end of the 6-month follow-up, 24% of patients with toric IOL implantation required prescription glasses of any type (bifocals, distance, or reading) compared to 64% of patients in the spherical IOL group.[@b37-opth-12-439]

Mingo-Botín et al conducted a randomized controlled trial (RCT) measuring spectacle dependence (defined as need to wear distance-vision spectacles) and patient satisfaction in cataract patients with PEA who were implanted with either toric IOLs (n=20) or spherical IOLs with PCRI (n=20).[@b38-opth-12-439] The VF-14 index was administered to patients prior to surgery and at 3 months after cataract surgery to assess functional impairment related to vision. Presurgery subjective patient satisfaction with vision was poor in both groups and a large increase in VF-14 index scores and reported satisfaction with vision was reported for both groups, with no significant difference between groups. Presurgery, 85% of patients in the toric IOL group and 80% of patients in the PCRI group wore spectacles to correct distance vision. At 3 months postoperatively, 15% of toric IOL patients required distance-vision spectacles compared to 45% of patients treated with spherical IOLs.[@b38-opth-12-439]

Holland et al conducted a large multicenter RCT comparing toric IOLs (n=256 patients) to spherical IOLs (n=261 patients) in cataract patients with PEA, and reported postoperative spectacle dependence (defined as any-use spectacles for distance vision) as one of the treatment outcomes. At 6 months postsurgery, 39% of patients with toric IOLs reported some degree of spectacle dependence for distance vision compared with 64% of those with spherical IOLs.[@b39-opth-12-439]

Ahmed et al conducted a single-arm prospective study to evaluate the efficacy of bilateral toric IOL implantation in astigmatic cataract patients (n=117).[@b40-opth-12-439] At 6 months postsurgery, 69% of patients reported independence (defined as no use of spectacles) from distance spectacles. Postsurgery, patients provided satisfaction ratings on a scale of 1 (completely unsatisfied) to 10 (completely satisfied), and 94% of patients rated their satisfaction as 7 or higher. Patient satisfaction was statistically significantly higher postoperatively at 6 months compared to preoperative values (*P*\<0.001).[@b40-opth-12-439]

Visser et al conducted an RCT in patients with bilateral cataract and bilateral astigmatism (n=86) in the Netherlands.[@b41-opth-12-439] One of the outcome measures was spectacle independence in patients who received bilateral toric (n=41) or aspherical (n=45) IOL implantation. At 6 months postoperatively, spectacle independence (defined as no use of spectacles) for distance vision was achieved in 84% of patients implanted with toric IOLs compared to 31% of patients implanted with aspherical IOLs (*P*\<0.01). At 6 months after cataract surgery, no significant differences were identified between the toric IOLs and aspherical IOLs for NEI RQL-42 subscales. Mean scores on the NEI RQL-42 satisfaction with corrections subscale was similar for patients implanted with toric or aspherical IOLs (87 and 83, respectively).[@b41-opth-12-439]

Mencucci et al conducted a prospective, observational study in patients with bilateral cataract and PEA (n=120) who underwent unilateral cataract surgery.[@b42-opth-12-439] Patients were implanted with either spherical or toric IOLs. Postoperatively, patients with toric IOLs achieved significantly better refractive and visual outcomes compared to spherical IOLs. At 3 months after cataract surgery, QoL results were significantly better for the toric IOL group compared to the spherical IOL group, measured using the NEI RQL-42 questionnaire. Further, QoL was significantly better for the toric IOL group compared to the spherical IOL group, measured on NEI RQL subscales related to astigmatism correction, such as clarity of vision (*P*\<0.001), far vision (*P*=0.021), glare (*P*=0.038), and satisfaction with correction (*P*=0.001).[@b42-opth-12-439]

In a prospective single-arm study with a 6-month follow-up, Knorz et al assessed patient experience with multifocal toric IOLs in Europe and South America.[@b43-opth-12-439] The VISTAS questionnaire was administered preoperatively and at all postoperative visits. Preoperatively, 63% of astigmatic cataract patients were completely dissatisfied with their overall vision, which was reduced to 2.4% after astigmatism correction with multifocal toric IOLs. Preoperatively, only 14% patients were spectacle-free, which had increased to 90% at 6 months after cataract surgery. On a scale of 0 (worst) to 10 (best), mean UCVA rating significantly improved from 3.63±1.98 preoperatively (n=38) to 7.89±1.87 at 6 months postoperatively (n=37) (*P*\<0.001).[@b43-opth-12-439]

Supuk et al conducted a prospective study in the UK to evaluate changes in dizziness and self-reported falls in cataract patients (n=283) with astigmatism before and after cataract surgery (monofocal IOLs). The self-reported fall rate among patients in the 6 months prior to cataract surgery was 23% and had decreased to 20% at 6 months postsurgery; however, findings were statistically nonsignificant. Sensitivity analysis showed a nonsignificant association between fall risk and magnitude of astigmatism.[@b44-opth-12-439]

Uncorrected astigmatism following cataract surgery appears to affect visual and refractive outcomes, leads to higher spectacle dependence, and is associated with low self-reported satisfaction with vision. This can in turn affect patients' vision-related QoL. A significant improvement in patient satisfaction was observed postsurgically after correction of astigmatism with toric IOLs. Postoperative spectacle dependence (defined as any use of spectacles) was lower with toric IOLs compared to monofocal IOLs. This review identified only one study that did not report any association between risk of falls and astigmatism.

Discussion
==========

To our knowledge, this is the first systematic review to study the prevalence, humanistic burden, and economic burden of astigmatism in patients with cataract undergoing surgery. This systematic review aimed to synthesize the evidence on the prevalence and economic and humanistic burden of astigmatism in cataract patients.

Based on the available data, there is high prevalence of PEA in cataract patients. The economic burden of astigmatism in cataract patients is mostly driven by postoperative costs of vision correction with spectacles. In addition, indirect costs, such as optometrist, travel, and caregivers' time, add further to the economic burden on patients and their families. The evidence suggests that astigmatism correction at the time of cataract surgery resulted in better postoperative visual outcomes that can lead to higher satisfaction with vision, reduced need for vision correction with spectacles, and subsequent greater improvement in patients' vision-related QoL compared to patients in whom astigmatism correction is not attempted during cataract surgery. In addition, astigmatism correction during cataract surgery is a cost-effective or cost-saving approach compared to postoperative vision correction with spectacles.

Despite these benefits, patients in predominantly publicly financed health-care systems prevalent in Europe might not get access to astigmatism correction during cataract surgery, since cataract-surgery reimbursement is governed by fixed tariffs that cover only standard monofocal IOLs. Besides, astigmatism correction during cataract surgery may not be the ultimate clinical goal in many health-care systems, since it can be managed by vision correction with spectacles in the postoperative period.

Currently, public payers do not reimburse the cost of spectacles in many countries, and thus astigmatism correction is not covered in their budgets. Therefore, patients who want to have astigmatism correction during cataract surgery will have to be either covered by their private health-care insurance or will have to pay out of pocket. However, in some systems, such as the UK and Spain, there is no provision for patient copay in public hospitals, and thus patients have almost no choice in choosing the most effective treatment for their astigmatism. On the other side, cataract patients with PEA in predominantly private health-care insurance systems, such as the US, could have access to more effective treatments, such as toric IOLs. A recent study has highlighted the importance of understanding the differences in what patients say about the need for correction, what they do, and how they function with or without correction. All these important aspects should be considered in understanding the construct of spectacle independence.[@b55-opth-12-439]

The evidence identified in this review had some inherent limitations. The data on prevalence of preoperative astigmatism has not been reported in many countries/regions, most significant of which is the US. The limited evidence on risk of falls and astigmatism in cataract patients suggests the need for more studies to investigate the risk. No population-based cost-of-illness study was identified, and the cost burden in preoperative astigmatic cataract patients is unknown. All the identified studies were interventional studies evaluating preoperative and postoperative economic and humanistic burden, meaning that study populations might not have been representative of astigmatic cataract patients. Further, we acknowledge that the reported economic burden in the published studies was an estimate from economic modeling methods, and then further discounting to 2017 prices could have led to an overestimation of cost data in our findings.

Nevertheless, this literature review has multiple strengths associated with the systematic review methodology. This review was conducted in accordance with the widely accepted Cochrane methodology. A comprehensive search strategy was used to identify the evidence from biomedical databases. In addition, conferences and bibliographies of included studies/literature reviews were hand-searched to identify any unpublished evidence. From a methodology perspective, limitations were mainly related to omission of non-English publications. Although we used a very long search period (1996--2016), some publications reporting data on prevalence and burden of astigmatism may have been missed.

Conclusion
==========

There is high prevalence of PEA in cataract patients. Although published data are limited, both preoperative astigmatism and postoperative residual astigmatism affect visual function and vision-related QoL, resulting in increased humanistic burden. Suboptimal correction of astigmatism during cataract surgery drives the continuous need for vision correction with spectacles in the postoperative period. Patients must bear the out-of-pocket expenses, since payers often do not reimburse the cost of spectacles. Greater access to astigmatism correction during cataract surgery can improve visual outcomes and QoL in patients. More research is required to gain a better understanding of the disease burden of astigmatism in cataract patients.
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![Prevalence of cataract eyes with ≥1 D of preexisting astigmatism.\
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![Distribution of preexisting astigmatic cataract eyes with mild, moderate, or significant astigmatism.\
**Note:** Based on the categorization reported by Lyall et al.[@b24-opth-12-439]\
**Abbreviations:** D, diopters; UK, United Kingdom.](opth-12-439Fig3){#f3-opth-12-439}

![Distribution of preexisting astigmatic cataract eyes by type of orientation.\
**Abbreviations:** ATR, against the rule; OA, oblique astigmatism; WTR, with the rule.](opth-12-439Fig4){#f4-opth-12-439}

###### 

Search strategy

       Search terms
  ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1    exp cataract/or exp capsule opacification/
  2    (cataract or (lens adj2 opac\*)).ab,ti,kw.
  3    exp refractive errors/or exp aniseikonia/or exp anisometropia/or exp astigmatism/or exp corneal wavefront aberration/or exp hyperopia/or exp myopia/or exp presbyopia/
  4    (astig\* or ametropia or myopi\* or Hyperopi\* or nearsightedness or farsightedness or (refractive adj2 (error or aberration))).ab,ti.
  5    1 or 2
  6    3 or 4
  7    5 and 6
  8    exp "Quality of Life"/
  9    exp quality-adjusted life years/
  10   (QoL or quality adjusted life year or QALY or hrqol or quality of life or DALY or disability adjusted life years or life year\* or patient reported outcome or (years adj3 lost)).ab,ti.
  11   (short-form 36 or SF-36 or SF-6D or euroqol or EQ-5D or HUI or health utility index).ab,ti.
  12   (National Eye Institute Visual Function Questionnaire or NEI VFQ or cataract TyPE specification questionnaire or visual activities questionnaire or visual disability assessment or visual function or quality of life questionnaire or VF-14 or VF-8 or catquest 9SF questionnaire or cataract outcomes questionnaire).ab,ti.
  13   "costs and cost analysis"/or exp "cost allocation"/or exp cost-benefit analysis/or exp "cost control"/or exp "cost of illness"/or exp "cost sharing"/or exp health care costs/or exp health expenditures/or exp economics, hospital/or exp hospital charges/or exp hospital costs/or exp economics, medical/or exp fees, medical/or exp economics, nursing/or exp economics, pharmaceutical/or exp fees, pharmaceutical/or exp prescription fees/
  14   exp "costs and cost analysis"/or exp "cost allocation"/or exp cost-benefit analysis/or exp "cost control"/or exp "cost savings"/or exp "cost of illness"/or exp "cost sharing"/or exp health care costs/or exp direct service costs/or exp drug costs/or exp employer health costs/or exp hospital costs/or exp health expenditures/
  15   exp Health Resources/
  16   exp hospitalization/or exp "length of stay"/or exp patient admission/or exp patient discharge/or exp patient readmission/or exp institutionalization/
  17   (cost\* or economic\* or price or hospitali\* or length of stay or expenditure or fee\* or pharmacoeconomic\* or resource\* or productivity\* or loss of work or absenteeism or presenteeism or cost effectiveness or cost benefit or incremental cost or ICER).ab,ti.
  18   exp epidemiology/or exp molecular epidemiology/or exp pharmacoepidemiology/
  19   exp morbidity/or exp incidence/or exp prevalence/or exp mortality/or exp molecular epidemiology/or exp epidemiologic study characteristics as topic/or exp epidemiologic studies/or exp epidemiologic research design/
  20   (epidemiolog\* or incidence\* or prevalen\* or mortality or death or survival or risk factor or co-morbid\* or morbid\* or mortalit\* or death or survival or die\* or natural history or disease progress\* or prognosis).ab,ti.
  21   18 or 19 or 20
  22   13 or 14 or 15 or 16 or 17
  23   8 or 9 or 10 or 11 or 12
  24   7 and 21
  25   7 and 22
  26   7 and 23
  27   24 or 25 or 26
  28   exp lenses, intraocular/or exp phakic intraocular lenses/
  29   (intraocular lens or IOL).ab,ti.
  30   28 or 29
  31   toric\*.mp.
  32   30 and 31
  33   7 and 32
  34   27 or 33
  35   Limit 34 to English language \[limit not valid in CDSR, ACP Journal Club, DARE, CLCMR; records were retained\]
  36   Limit 35 to human \[limit not valid in CDSR, ACP Journal Club, DARE, CCTR, CLCMR; records were retained\]
  37   Limit 36 to humans \[limit not valid in CDSR, ACP Journal Club, DARE, CCTR, CLCMR; records were retained\]
  38   Remove duplicates from 37

###### 

Characteristics of studies reporting prevalence of preexisting astigmatism

  Study                                            Design                 Location      Sites/centers   Period                         Sample size   Age (years), mean ± SD   Female (%)                                       Astigmatism (D), mean ± SD   
  ------------------------------------------------ ---------------------- ------------- --------------- ------------------------------ ------------- ------------------------ ------------------------------------------------ ---------------------------- --------------------------------------------------
  Behndig et al[@b13-opth-12-439]                  Retrospective cohort   Sweden        Multicenter     2008--2010                     17,056        NR                       NR                                               NR                           NR
  Chen et al[@b14-opth-12-439]                     Cross-sectional        China         Single-center   July 2009--May 2011            4,831         2,849                    70.6±9.6                                         61.7                         1.01±0.69
  Cui et al[@b15-opth-12-439],[@b20-opth-12-439]   Cross-sectional        China         Single-center   2007--2011                     6,750         4,561                    70.4±10.5                                        55.6                         0.9[\*](#tfn1-opth-12-439){ref-type="table-fn"}
  De Bernardo et al[@b16-opth-12-439]              Retrospective cohort   Italy         Single-center   January 2012--April 2013       757           380                      71.9±10.2                                        53.7                         1.02±0.69
  Ercegović et al[@b17-opth-12-439]                Retrospective cohort   Croatia       Single-center   April 2011--June 2011          392           202                      77[\*](#tfn1-opth-12-439){ref-type="table-fn"}   55                           0.75[\*](#tfn1-opth-12-439){ref-type="table-fn"}
  Ferrer-Blasco et al[@b18-opth-12-439]            Prospective            Spain         Single-center   NR                             4,540         2,415                    60.6±9.9                                         68.2                         0.9±0.9
  Guan et al[@b19-opth-12-439]                     Cross-sectional        China         Single-center   November 2009--November 2011   1,430         827                      72.3±11.6                                        56.6                         1.07±0.73
  Hoffman and Hütz[@b21-opth-12-439]               Retrospective cohort   Germany       Single-center   2000--2006                     23,239        15,448                   74[\*](#tfn1-opth-12-439){ref-type="table-fn"}   NR                           NR
  Khan and Muhtaseb[@b22-opth-12-439]              Cross-sectional        UK            Single-center   NR                             1,230         746                      75.5±10.7                                        54                           1.03±0.73
  Lekhanont et al[@b23-opth-12-439]                Prospective            Thailand      Single-center   January 2008--September 2010   2,010         1,005                    68.2±9.2                                         61.4                         1.05±0.62
  Lyall et al[@b24-opth-12-439]                    Prospective cohort     Scotland      Single-center   NR                             3,498         1,814                    74.5±10.2                                        60.1                         1.04±0.78
  Miyake et al[@b25-opth-12-439]                   Retrospective          Japan         Single-center   April 2002--September 2009     12,428        7,187                    69.9±12.1                                        NR                           1.02±0.81
  Oh et al[@b26-opth-12-439]                       Retrospective cohort   South Korea   Single-center   May 2009--July 2013            2,847         2,847                    66.6±12.1                                        64.2                         0.79±0.64
  Ostri et al[@b27-opth-12-439]                    Cross-sectional        Denmark       Single-center   January 2002--December 2013    21,524        14,071                   72±12                                            61                           1.06±0.9
  Prakairungthong et al[@b28-opth-12-439]          Retrospective cohort   Thailand      Single-center   October 2010--September 2011   2,688         2,671                    66.2±10.8                                        57                           1.09±0.87
  Riley et al[@b29-opth-12-439]                    Prospective            New Zealand   Single-center   January 1997--March 2000       502           488                      74.9±9.8                                         NR                           NR
  Westin et al[@b30-opth-12-439]                   Retrospective cohort   Sweden        Unclear         March 2013                     6,712         NR                       73.8±9.3                                         60.5                         −0.71±0.78
  Yuan et al[@b31-opth-12-439]                     Retrospective cohort   China         Multicenter     May 2012--April 2013           12,449        6,908                    69.8±11.2                                        53.7                         1.15±0.84

**Note:**

Median.

**Abbreviations:** NR, not reported; D, diopters; SD, standard deviation; UK, United Kingdom.

###### 

Characteristics of studies reporting economic burden

  Study                                Design                        Location        Cost year   Sample size   Age (years), mean   Female, %   Astigmatism (D), mean   
  ------------------------------------ ----------------------------- --------------- ----------- ------------- ------------------- ----------- ----------------------- --------
  Laurendeau et al[@b32-opth-12-439]   Cost--consequence analysis    Multinational   2006        NR            NR                  70          NR                      NR
  Pineda et al[@b33-opth-12-439]       Cost--utility analysis        USA             2008        NR            NR                  ≥65         NR                      1.5--3
  Ochoa et al[@b34-opth-12-439]        Cost-effectiveness analysis   Colombia        2013        NR            NR                  NR          NR                      \>0.75
  Colin et al[@b36-opth-12-439]        Retrospective cohort          France          NR          NR            580,253             73.6        66.7                    NR
  Kim et al[@b35-opth-12-439]          Cross-sectional               South Korea     NR          NR            150                 \>45        NR                      NR

**Note:** For all studies, costs have been inflated from base year to 2017 and converted to US\$.

**Abbreviations:** D, diopters; USA, United States of America; NR, not reported.

###### 

Characteristics of studies reporting humanistic burden

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                 Design        Location                   Sites/centers   Period                      Follow-up   Sample size   Age (years), mean ± SD   Female, %                  Astigmatism (D), mean ± SD   
  ------------------------------------- ------------- -------------------------- --------------- --------------------------- ----------- ------------- ------------------------ -------------------------- ---------------------------- --------------------------
  Knorz et al[@b43-opth-12-439]         Prospective   Europe and South America   Multicenter     NR                          6 months    88            44                       62.5                       68.2                         NR

  Lane et al[@b37-opth-12-439]          RCT           USA                        Multicenter     NR                          6 months    62            62                       Toric IOL: 69.1±11.9\      50                           NR
                                                                                                                                                                                Spherical IOL: 74.5±9.2                                 

  Mingo-Botín et al[@b38-opth-12-439]   Prospective   Spain                      Single-center   May 2008--June 2009         3 months    40            40                       Toric IOL: 71.5±11.1\      NR                           Toric IOL: 1.82±0.37\
                                                                                                                                                                                Spherical IOL: 75.6±5.9                                 Spherical IOL: 2.17±1.03

  Holland et al[@b39-opth-12-439]       RCT           USA                        Multicenter     NR                          12 months   NR            517                      71                         55.1                         NR

  Ahmed et al[@b40-opth-12-439]         Single-arm    Canada                     Multicenter     NR                          6 months    240           120                      68±11                      65.8                         1.7±0.4

  Visser et al[@b41-opth-12-439]        RCT           the Netherlands            Multicenter     February 2010--March 2012   6 months    172           86                       74                         48.8                         Toric IOL: 2.02±0.95\
                                                                                                                                                                                                                                        Nontoric IOL: 2±0.84

  Mencucci et al[@b42-opth-12-439]      Prospective   Italy                      NR              NR                          3 months    120           120                      Toric IOL: 73.9±11.4\      65.8                         Toric IOL: −2.42±0.77\
                                                                                                                                                                                Monofocal IOL: 77.1±6.7\                                Monofocal IOL: −2±1.07\
                                                                                                                                                                                Control: 75.05±8.7                                      Control: −0.68±0.24

  Supuk et al[@b44-opth-12-439]         Single-arm    UK                         Multicenter     July 2012--July 2013        6 months    NR            287                      76.5±6.3                   55                           NR
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** IOL, intraocular lens; NR, not reported; RCT, randomized controlled trial.

###### 

Instruments used to evaluate quality of life in astigmatic patients with cataract

  Instrument             Summary
  ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NEI RQL-42             This is a 42-item questionnaire that measures patients' satisfaction with distance vision, clarity of vision, and severity and frequency of glare symptoms, along with the need for spectacles. The scale ranges 0--100, with higher scores indicating better QoL and less dependence on corrective wear (such as spectacles or contact lenses).
  VISTAS questionnaire   The questionnaire has three sections. Section I has questions related to subjective experience with tasks at a range of distances with and without corrective wear. The near-task section comprises ten questions to assess visual acuity less than 50 cm from the patient. The intermediate-task section comprises 12 questions to assess the patient's vision at distances of 50--90 cm. The near-distance-task section comprises 13 questions to assess the patient's vision from 90 cm to 4 m. The distance-task section comprises 15 questions to assess vision from more than 4 m away. Section II of the questionnaire evaluates the patient's use of corrective wear and reliance on it. Section III of the questionnaire evaluates vision without corrective wear, and includes an assessment of patient satisfaction for daytime and nighttime vision. Potential responses for section I of the questionnaire are 1= no difficulty, 2= minor difficulty, 3= moderate difficulty, 4= major difficulty, 5= cannot accomplish, and 6= not applicable. A response of "not applicable" could be selected if participants did not perform a task for reasons other than poor vision or if corrective wear was not worn for the task. Responses for section II, assessing use of corrective wear, are "none of the time", "some of the time", "half of the time", "most of the time", and "all the time".
  VF-14                  The VF-14 is a brief questionnaire designed to measure functional impairment on patients due to cataract. It consists of 18 questions covering 14 aspects of visual function affected by cataracts.

**Abbreviations:** NEI RQL-42, National Eye Institute Refractive Error Quality of Life; VF, Visual Function (index); QoL, quality of life; VISTAS, Visual Tasks Difficulty Assessment.
